Hiroshi Nagabukuro
Vorstandsvorsitzender bei ARTham Therapeutics, Inc.
Aktive Positionen von Hiroshi Nagabukuro
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ARTham Therapeutics, Inc.
ARTham Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million. | Direktor/Vorstandsmitglied | 01.07.2018 | - |
Vorstandsvorsitzender | 01.07.2018 | - | |
Präsident | 01.07.2018 | - |
Karriereverlauf von Hiroshi Nagabukuro
Statistik
International
Japan | 2 |
Operativ
Director/Board Member | 1 |
Chief Executive Officer | 1 |
President | 1 |
Sektoral
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
ARTham Therapeutics, Inc.
ARTham Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million. | Health Technology |
- Börse
- Insiders
- Hiroshi Nagabukuro
- Erfahrung